{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:14:46Z","timestamp":1791026086606,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.euroneuro.2011.07.004","type":"journal-article","created":{"date-parts":[[2011,8,14]],"date-time":"2011-08-14T15:01:50Z","timestamp":1313334110000},"page":"S703-S709","source":"Crossref","is-referenced-by-count":65,"special_numbering":"S4","title":["Agomelatine: A narrative review"],"prefix":"10.1016","volume":"21","author":[{"given":"Koen","family":"Demyttenaere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2011.07.004_bb0005","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s00406-008-0849-0","article-title":"The effects of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis","volume":"259","author":"Bauer","year":"2009","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0010","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"issue":"Suppl 22","key":"10.1016\/j.euroneuro.2011.07.004_bb0015","first-page":"30","article-title":"Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events","volume":"62","author":"Demyttenaere","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2011.07.004_bb0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4088\/PCC.08m00748blu","article-title":"\u201cCaseness\u201d for depression and anxiety in a depressed outpatient population: symptomatic outcome as a function of baseline diagnostic categories","volume":"11","author":"Demyttenaere","year":"2009","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0025","series-title":"Valdoxan (Agomelatine): Summary of Product Characteristics","author":"European Marketing Authorization","year":"2009"},{"issue":"1","key":"10.1016\/j.euroneuro.2011.07.004_bb0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.2009.1943","article-title":"Antidepressant drug effects and depression severity: a patient-level meta-analysis","volume":"303","author":"Fournier","year":"2010","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.euroneuro.2011.07.004_bb0035","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/ebmh.12.4.98","article-title":"Are all antidepressants equal?","volume":"12","author":"Gartlehner","year":"2009","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrneurol.2009.51","article-title":"Are some antidepressants better than others?","volume":"5","author":"Gartlehner","year":"2009","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.euroneuro.2011.07.004_bb0045","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/jcp.0b013e31815152a5","article-title":"Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence","volume":"27","author":"Goethe","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0050","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.4088\/JCP.08m04548","article-title":"Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial","volume":"70","author":"Goodwin","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/YIC.0b013e32833a86aa","article-title":"Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study","volume":"25","author":"Hale","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0060","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4088\/JCP.09m05347blu","article-title":"Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline","volume":"71","author":"Kasper","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0171","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jad.2009.08.011","article-title":"Rethinking depression and the actions of antidepressants: uncovering the links between the neural and behavioral elements","volume":"120","author":"Katz","year":"2010","journal-title":"J. Affect. Disorders"},{"issue":"2","key":"10.1016\/j.euroneuro.2011.07.004_bb0065","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.euroneuro.2005.09.002","article-title":"Placebo-controlled trial of agomelatine in the treatment of major depressive disorder","volume":"16","author":"Kennedy","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2011.07.004_bb0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/11534420-000000000-00000","article-title":"Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness","volume":"24","author":"Kennedy","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/JCP.0b013e318172b48c","article-title":"A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR","volume":"28","author":"Kennedy","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2011.07.004_bb0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1185\/03007990802622726","article-title":"Escitalopram in the treatment of major depressive disorder: a meta-analysis","volume":"25","author":"Kennedy","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.euroneuro.2011.07.004_bb0085","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1371\/journal.pmed.0050045","article-title":"2008 initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration","volume":"5","author":"Kirsch","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0090","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-2006-949148","article-title":"The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: an extended analysis","volume":"39","author":"Lam","year":"2006","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0095","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.4088\/JCP.v68n1112","article-title":"Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine","volume":"68","author":"Lemoine","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0100","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00004850-200209000-00004","article-title":"Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study","volume":"17","author":"Loo","year":"2002","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0105","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.euroneuro.2008.06.003","article-title":"A regulatory Apologia\u2014 a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants","volume":"18","author":"Melander","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/0269881108096507","article-title":"Better sexual acceptability of agomelatine (25 and 50mg) compared with paroxetine (20mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale","volume":"24","author":"Montejo","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"11","key":"10.1016\/j.euroneuro.2011.07.004_bb0115","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.4088\/JCP.v66n1110","article-title":"Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine","volume":"66","author":"Nelson","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0120","first-page":"661","article-title":"Efficacy of agomelatine, a MT1\/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder","volume":"10","author":"Oli\u00e9","year":"2007","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2011.07.004_bb0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2008.08.009","article-title":"Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD","volume":"19","author":"Papakostas","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.euroneuro.2011.07.004_bb0130","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.biopsych.2007.08.010","article-title":"Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches","volume":"63","author":"Papakostas","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2011.07.004_bb0135","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.eurpsy.2009.07.012","article-title":"Duration and adherence of antidepressant treatment (2003 to 2007) based on prescription database","volume":"25","author":"Serna","year":"2010","journal-title":"Eur. Psychiatry"},{"issue":"11","key":"10.1016\/j.euroneuro.2011.07.004_bb0140","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2165\/00023210-200822110-00005","article-title":"Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and\/or anxiety disorders","volume":"22","author":"Sheehan","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0145","doi-asserted-by":"crossref","first-page":"616","DOI":"10.4088\/JCP.09m05471blu","article-title":"Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial","volume":"71","author":"Stahl","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2011.07.004_bb0155","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1176\/appi.ajp.2008.08071027","article-title":"Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report","volume":"166","author":"Wisniewski","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0160","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/JCP.0b013e3181d420a7","article-title":"Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"30","author":"Zajecka","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2011.07.004_bb0165","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1176\/appi.ajp.159.3.469","article-title":"Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice?","volume":"159","author":"Zimmerman","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.07.004_bb0170","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1176\/appi.ajp.161.7.1285","article-title":"Which factors influence psychiatrists' selection of antidepressants?","volume":"161","author":"Zimmerman","year":"2004","journal-title":"Am. J. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X11001581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X11001581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T14:54:36Z","timestamp":1543589676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X11001581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":35,"alternative-id":["S0924977X11001581"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2011.07.004","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}